PMID- 15946204
OWN - NLM
STAT- MEDLINE
DCOM- 20050922
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 3
IP  - 6
DP  - 2005 Jun
TI  - The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of 
      thrombosis in patients with the lupus anticoagulant.
PG  - 1160-5
AB  - BACKGROUND: Lupus anticoagulant (LA) is a strong risk factor of thrombosis. 
      However, a subgroup of patients positive for LA is unaffected by thrombosis and 
      currently no predictive markers are available to identify patients positive for 
      LA at increased risk for thrombosis. OBJECTIVE: The aim of the study was to 
      investigate whether anti-beta-2-glycoprotein I (anti-beta2GPI) or anticardiolipin 
      antibodies (ACA) are associated with an increased risk of thrombosis in patients 
      persistently positive for LA. PATIENTS AND METHODS: A cohort of 87 consecutive 
      patients persistently positive for LA was investigated, 55 with and 32 without a 
      history of thrombosis. Immunoglobulin G (IgG) and M (IgM) antibodies against 
      beta2GPI and cardiolipin were determined by enzyme-linked immunoassay. RESULTS: 
      Patients positive for LA with thrombosis had significantly higher levels of 
      anti-beta2GPI IgG (median 16.7 standard units, interquartile range 3.0-75.2, P = 
      0.002) and of ACA IgG (41.1 IgG phospholipid units per mL, 8.9-109.0, P = 0.002) 
      than those without thrombosis (2.6, 1.4-7.9 and 9.7, 4.6-22.1, respectively). 
      Levels of anti-beta2GPI IgM and ACA IgM did not differ significantly between LA 
      patients with and without thrombosis (P = 0.25 and 0.12, respectively). Elevated 
      anti-beta2GPI IgG was associated with an increased risk for thrombosis (OR = 4.0, 
      95% CI 1.2-13.1), especially for venous thromboembolism (OR = 5.2, 95% CI 
      1.5-18.0). CONCLUSIONS: Increased levels of anti-beta2GPI IgG were associated 
      with thrombosis. We conclude that anti-beta2GPI IgG levels above normal predict 
      an increased risk of thrombosis in patients persistently positive for LA.
FAU - Zoghlami-Rintelen, C
AU  - Zoghlami-Rintelen C
AD  - Division of Haematology and Blood Coagulation, Department of Internal Medicine I, 
      Medical University Vienna, Vienna, Austria.
FAU - Vormittag, R
AU  - Vormittag R
FAU - Sailer, T
AU  - Sailer T
FAU - Lehr, S
AU  - Lehr S
FAU - Quehenberger, P
AU  - Quehenberger P
FAU - Rumpold, H
AU  - Rumpold H
FAU - Male, C
AU  - Male C
FAU - Pabinger, I
AU  - Pabinger I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Autoantibodies)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
CIN - J Thromb Haemost. 2005 Jun;3(6):1158-9. PMID: 15946203
MH  - Adult
MH  - Antibodies, Anticardiolipin/blood
MH  - Autoantibodies/*blood
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glycoproteins/*immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Lupus Coagulation Inhibitor/*blood
MH  - Male
MH  - Middle Aged
MH  - *Predictive Value of Tests
MH  - Risk
MH  - Thrombosis/etiology/*immunology
MH  - beta 2-Glycoprotein I
EDAT- 2005/06/11 09:00
MHDA- 2005/09/24 09:00
CRDT- 2005/06/11 09:00
PHST- 2005/06/11 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/06/11 09:00 [entrez]
AID - S1538-7836(22)16049-6 [pii]
AID - 10.1111/j.1538-7836.2005.01394.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2005 Jun;3(6):1160-5. doi: 10.1111/j.1538-7836.2005.01394.x.